10X Genomics Hits Day High with 11.72% Surge, Outperforming Market

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant surge in its stock price, gaining 11.72% on June 15, 2026. The stock reached an intraday high of USD 32.33, reflecting strong market activity. Over the past month, 10X Genomics has shown impressive performance, with a 51.98% increase, significantly outpacing the S&P 500's 1.97% gain during the same period. In the last year, the company has delivered a remarkable return of 209.36%, compared to the S&P 500's 26.39%. This performance is underscored by positive results over the last five consecutive quarters, with operating cash flow reaching its highest at USD 127.82 million. The company's debt-equity ratio stands at a low -56.3%, indicating a strong financial position relative to its equity. Despite its recent successes, the stock is considered risky compared to historical valuations, with institutional holdings at 100%, suggesting a robust analytical backing from larger investors. Overall, 10X Genomics continues to demonstrate notable market performance amidst a dynamic industry landscape.